ArticleJournal of community hospital internal medicine perspectives2025
Concurrent Histoplasmosis & Blastomycosis in a Young Woman.
Article in Journal of community hospital internal medicine perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Histoplasmosis capsulatum and Case description: A 35-year-old female with a medical history significant for HIV and substance use disorder presented to the hospital with severe lower abdominal pain, weakness, and unintentional weight loss. Her symptoms persisted and evolved to include dyspnea and high fevers. Imaging with chest CT revealed diffuse miliary lung patterns. Confirmation of histoplasmosis was noted by in-house blood cultures. Additional testing via send-out laboratory confirmed the presence of Conclusion: Current treatment of histoplasmosis in immunocompetent individuals depends on the duration of the disease. Acute infections do not warrant treatment. If symptoms persist, a three-month course of itraconazole is recommended. Amphotericin B is considered in patients unable to take itraconazole or for those with severe disease. Blastomycosis ranges from asymptomatic to a deadly pulmonary infection. While spontaneous remission of mildly symptomatic blastomycosis can occur, treatment with itraconazole is often recommended. Amphotericin B is reserved for severe pulmonary infection, disseminated blastomycosis, or central nervous system blastomycosis. Immunocompromised patients represent a population at significantly elevated risk for disseminated fungal disease as well as severe pulmonary infection from fungal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.